1,255 Shares in Amgen Inc. (NASDAQ:AMGN) Purchased by May Hill Capital LLC

May Hill Capital LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,255 shares of the medical research company’s stock, valued at approximately $327,000.

Other large investors also recently modified their holdings of the company. Lokken Investment Group LLC grew its position in Amgen by 2.1% in the fourth quarter. Lokken Investment Group LLC now owns 4,121 shares of the medical research company’s stock valued at $1,074,000 after acquiring an additional 85 shares during the period. Geode Capital Management LLC grew its holdings in shares of Amgen by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 12,475,032 shares of the medical research company’s stock worth $3,245,881,000 after purchasing an additional 352,143 shares during the last quarter. StoneX Group Inc. increased its position in shares of Amgen by 46.2% during the 4th quarter. StoneX Group Inc. now owns 18,460 shares of the medical research company’s stock worth $4,811,000 after purchasing an additional 5,836 shares in the last quarter. Tradewinds LLC. lifted its holdings in Amgen by 102.3% during the 4th quarter. Tradewinds LLC. now owns 5,371 shares of the medical research company’s stock valued at $1,400,000 after purchasing an additional 2,716 shares during the last quarter. Finally, Franklin Resources Inc. boosted its position in Amgen by 52.7% in the fourth quarter. Franklin Resources Inc. now owns 3,291,975 shares of the medical research company’s stock valued at $858,020,000 after buying an additional 1,135,884 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 1.5 %

Shares of NASDAQ AMGN opened at $311.55 on Tuesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market cap of $167.37 billion, a price-to-earnings ratio of 41.26, a P/E/G ratio of 2.63 and a beta of 0.53. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The company’s fifty day moving average is $301.87 and its 200-day moving average is $297.81.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Equities research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.06%. The ex-dividend date is Friday, May 16th. Amgen’s dividend payout ratio is 126.09%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now owns 7,210 shares in the company, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares in the company, valued at approximately $11,240,533.68. This trade represents a 40.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 69,341 shares of company stock worth $20,644,335 over the last ninety days. Company insiders own 0.69% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the subject of a number of research analyst reports. Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 target price on shares of Amgen in a research note on Thursday, January 2nd. Johnson Rice set a $294.00 price objective on Amgen in a research note on Wednesday, March 5th. Bank of America increased their target price on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. UBS Group reaffirmed a “hold” rating on shares of Amgen in a report on Wednesday, February 12th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $324.00 price objective on shares of Amgen in a research report on Friday, January 24th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $314.04.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.